Premium
Erythema nodosum induced by Covid‐19 Pfizer‐BioNTech mRNA vaccine: A case report and brief literature review
Author(s) -
Chahed Ferdaous,
Ben Fadhel Najah,
Ben Romdhane Haifa,
Youssef Monia,
Ben Hammouda Seifeddine,
Chaabane Amel,
Aouam Karim,
Ben Fredj Nadia
Publication year - 2023
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.15351
Subject(s) - erythema nodosum , medicine , panniculitis , sarcoidosis , erythema , dermatology , erythema multiforme , granulomatous inflammation , covid-19 , immunology , pathology , disease , infectious disease (medical specialty)
Erythema nodosum (EN), the most common form of panniculitis, is a reactive inflammation of the subcutaneous fat clinically presented with a sudden onset of painful, erythematous, nodular, subcutaneous lesions, typically localized to the pretibial area. EN is commonly caused by numerous infections (especially beta‐haemolytic streptococcal infections), autoimmune diseases (sarcoidosis), inflammatory bowel conditions and drugs. EN induced by Covid‐19 vaccines is rarely reported. We describe an original clinical observation of a 75‐year‐old woman who presented with EN after receiving the second dose of BNT162b2, an mRNA vaccine.